6-K ·Filed Sep 4, 2026
Actionable Insight • Neutral
Monitor for any capital markets strategy updates or financing activities given the new CFO's background and the company's recent de-SPAC and financial challenges disclosed in the June 2026 20-F.
Latest settled — T+20d ⚠ clustered
VRXA ▼ -35.80% at T+20d
NEUTRAL call -35.80% · α vs SPY -36.40% · entry $1.76 → $1.13
Latest observation: T+34 +197.88% FF3 residual α
T+1d
-9.09%
call -9.09% · α -8.54%
$1.60
settled 7w ago
T+5d
-7.39%
call -7.39% · α -6.18%
$1.63
settled 6w ago
T+20d
-35.80%
call -35.80% · α -36.40%
$1.13
settled 22d ago
T+60d
Pending
in 5w
Price Chart
Loading chart...
Executive Summary
Veraxa Biotech AG appointed Raju Willener as CFO effective September 4, 2026. Mr. Willener brings over 30 years of capital markets and corporate finance experience, including senior roles at global financial institutions. This is a routine leadership change with no new financial information disclosed.
Key Facts
- Raju Willener appointed CFO effective September 4, 2026
- Willener has over 30 years of experience in investment banking, corporate finance, and asset management
- Former CFO Carl von Halem thanked for his support
- No financial figures or guidance provided in the filing
Financial Impact
Not specified
Risk Factors
- No material risks from this filing; however, the company's accumulated deficit of CHF 98.5M and material weakness in internal controls per the prior 20-F remain concerns
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (VRXA) — Batch item 1 | 0001829126-26-009752 |
| Document: veraxabiotechag_6k.htm | 0001829126-26-009752 |
| Document: 0001829126-26-009752-index-headers.html | 0001829126-26-009752 |
| Document: 0001829126-26-009752-index.html | 0001829126-26-009752 |
| Document: 0001829126-26-009752.txt | 0001829126-26-009752 |
| 6-K Filing (VRXA) — Batch item 6 | 0001829126-26-009752 |
| Document: veraxabiotechag_6k.htm | 0001829126-26-009752 |
| Document: 0001829126-26-009752-index-headers.html | 0001829126-26-009752 |
| Document: 0001829126-26-009752-index.html | 0001829126-26-009752 |
| Document: 0001829126-26-009752.txt | 0001829126-26-009752 |
16 reports for VRXA
100% Hit rate @ T+20 Went positive at some point 5 of 5 best @ T+60▲ +71.84%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $1.11 | awaiting T+20 | — | $0.9800 (−11.71%) |
Sep 4, 2026 7w ago | 6-K | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Sep 4, 2026 7w ago | Press Release | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Aug 24, 2026 9w ago | 6-K | $1.78 $1.46 | ▼ −17.98% | ▼ −17.99% | $0.9800 (−44.94%) |
Aug 10, 2026 11w ago | EFFECT | $1.85 $1.60 | ▲ +13.51% | ▲ +12.60% | $0.9800 (+47.03%) |
Aug 7, 2026 11w ago | EFFECT | $1.99 $1.76 | ▲ +11.56% | ▲ +11.16% | $0.9800 (+50.75%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 27, 2026 13w ago | 6-K | $1.98 $1.73 | ▼ −12.63% | ▼ −16.01% | $0.9800 (−50.51%) |
Jul 27, 2026 13w ago | 6-K | $2.01 $1.78 | ▼ −11.44% | ▼ −14.74% | $0.9800 (−51.24%) |
Showing 10 of 16
US Market Status
Market Closed — Opens in 6h 20m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers